-$0.81 Earnings Per Share Expected for Mirati Therapeutics, Inc. (NASDAQ:MRTX) This Quarter
Equities analysts expect Mirati Therapeutics, Inc. (NASDAQ:MRTX) to post earnings per share (EPS) of ($0.81) for the current quarter, according to Zacks. Zero analysts have provided estimates for Mirati Therapeutics’ earnings, with estimates ranging from ($0.87) to ($0.74). Mirati Therapeutics reported earnings per share of ($1.11) in the same quarter last year, which suggests a positive year over year growth rate of 27%. The company is scheduled to issue its next earnings report on Thursday, August 3rd.
According to Zacks, analysts expect that Mirati Therapeutics will report full year earnings of ($3.21) per share for the current year, with EPS estimates ranging from ($3.36) to ($2.99). For the next fiscal year, analysts anticipate that the firm will post earnings of ($2.42) per share, with EPS estimates ranging from ($2.61) to ($2.27). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Mirati Therapeutics.
A number of analysts recently weighed in on the stock. ValuEngine cut shares of Mirati Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Jefferies Group LLC reiterated a “hold” rating and set a $5.50 price target on shares of Mirati Therapeutics in a research note on Wednesday, April 12th. Finally, Zacks Investment Research upgraded shares of Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research note on Wednesday, May 3rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $7.54.
A number of hedge funds have recently modified their holdings of MRTX. KCG Holdings Inc. acquired a new stake in shares of Mirati Therapeutics during the first quarter worth $106,000. Trexquant Investment LP increased its position in shares of Mirati Therapeutics by 62.2% in the first quarter. Trexquant Investment LP now owns 42,879 shares of the biotechnology company’s stock worth $223,000 after buying an additional 16,447 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Mirati Therapeutics by 22.9% in the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock worth $328,000 after buying an additional 11,753 shares during the last quarter. Omega Advisors Inc. purchased a new position in shares of Mirati Therapeutics during the first quarter worth approximately $520,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Mirati Therapeutics during the first quarter worth approximately $677,000. Hedge funds and other institutional investors own 64.60% of the company’s stock.
Shares of Mirati Therapeutics (MRTX) traded up 1.02% on Monday, hitting $4.95. 155,021 shares of the company traded hands. Mirati Therapeutics has a 12 month low of $2.70 and a 12 month high of $7.22. The company’s market capitalization is $123.45 million. The stock’s 50-day moving average price is $3.58 and its 200-day moving average price is $4.58.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.